- Home
- BREA vs EDSA Comparison
BREA vs EDSA Comparison
Compare BREA & EDSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BREA
- EDSA
- Stock Information
- Founded
- BREA 2022
- EDSA 2015
- Country
- BREA Ireland
- EDSA Canada
- Employees
- BREA N/A
- EDSA N/A
- Industry
- BREA Services-Misc. Amusement & Recreation
- EDSA Biotechnology: Pharmaceutical Preparations
- Sector
- BREA Consumer Discretionary
- EDSA Health Care
- Exchange
- BREA Nasdaq
- EDSA Nasdaq
- Market Cap
- BREA 14.8M
- EDSA 17.2M
- IPO Year
- BREA 2023
- EDSA N/A
- Fundamental
- Price
- BREA $7.64
- EDSA $2.43
- Analyst Decision
- BREA
- EDSA Strong Buy
- Analyst Count
- BREA 0
- EDSA 2
- Target Price
- BREA N/A
- EDSA $13.00
- AVG Volume (30 Days)
- BREA 216.2K
- EDSA 16.6K
- Earning Date
- BREA 01-01-0001
- EDSA 08-08-2025
- Dividend Yield
- BREA N/A
- EDSA N/A
- EPS Growth
- BREA N/A
- EDSA N/A
- EPS
- BREA N/A
- EDSA N/A
- Revenue
- BREA $2,988,009.00
- EDSA N/A
- Revenue This Year
- BREA N/A
- EDSA N/A
- Revenue Next Year
- BREA N/A
- EDSA N/A
- P/E Ratio
- BREA N/A
- EDSA N/A
- Revenue Growth
- BREA 151.51
- EDSA N/A
- 52 Week Low
- BREA $5.00
- EDSA $1.55
- 52 Week High
- BREA $19.50
- EDSA $5.00
- Technical
- Relative Strength Index (RSI)
- BREA 63.62
- EDSA 51.55
- Support Level
- BREA $5.87
- EDSA $2.41
- Resistance Level
- BREA $14.84
- EDSA $2.47
- Average True Range (ATR)
- BREA 0.96
- EDSA 0.08
- MACD
- BREA 0.19
- EDSA -0.01
- Stochastic Oscillator
- BREA 21.14
- EDSA 48.15
About BREA Brera Holdings PLC
Brera Holdings PLC focused on expanding social impact football by developing a international portfolio of emerging football clubs with increased opportunities to earn tournament prizes, gain sponsorships, and provide other professional football and related consulting services.
About EDSA Edesa Biotech Inc.
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.